ストックスクリーナーアプリを入手
1.42
0.70%
-0.01
アフターアワーズ：
1.40
-0.02
-1.41%
前日終値:
$1.43
開ける：
$1.44
24時間の取引高:
54,125
Relative Volume:
0.50
時価総額：
$22.59M
収益：
$345.00K
当期純損益:
$-11.25M
株価収益率:
-1.9676
EPS:
-0.7217
ネットキャッシュフロー:
$-16.70M
1週間 パフォーマンス:
+0.71%
1か月 パフォーマンス:
+8.40%
6か月 パフォーマンス:
+35.24%
1年 パフォーマンス:
-17.92%
1日の値動き範囲:
$1.40
$1.45
1週間の範囲:
$1.32
$1.49
52週間の値動き範囲:
$0.7687
$2.06
Allarity Therapeutics Inc Stock (ALLR) Company Profile
名前
Allarity Therapeutics Inc
セクター
電話
401-426-4664
住所
24 SCHOOL ST., 2ND FLOOR, BOSTON
Compare ALLR vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALLR
Allarity Therapeutics Inc
|
1.42 | 22.75M | 345.00K | -11.25M | -16.70M | -0.7217 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allarity Therapeutics Inc Stock (ALLR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-28 | 開始されました | Ascendiant Capital Markets | Buy |
Allarity Therapeutics Inc (ALLR) 最新ニュース
Allarity Therapeutics Stock Price Forecast. Should You Buy ALLR? - StockInvest.us
Allarity Therapeutics Inc (ALLR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Allarity Therapeutics Inc (ALLR) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Allarity Therapeutics Inc (ALLR) Peer Comparison – Compare with Others - Value Research
Allarity (ALLR) Financial Update: EPS Clears the Reported Estimate in the Latest Session; Trading Response: The Stock Closes Near Unchanged at the CloseEBITDA Estimate Trend - vinanet.vn
Allarity (ALLR) Earnings Update: The Available Earnings Metric Delivers a Beat; Price Move: Shares Move 5.93% Higher for the Current SessionEarnings Seasonality - vinanet.vn
Allarity Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Allarity Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign - Investing News Network
Allarity Therapeutics Q2 EPS of $(0.21) beats $(0.25) estimate - scanx.trade
Allarity Therapeutics reports Q2 results, cash position - Investing.com
Allarity Therapeutics, Inc. 2026: Revenue $0 Net income ($3.41M), EPS ($0.21) — 10-Q Summary - TradingView
Allarity Therapeutics reports Q2 results, cash position By Investing.com - Investing.com Canada
Allarity Therapeutics (ALLR) adds $20M debt, holds $26.9M cash in Q2 2026 - Stock Titan
Allarity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready ... - Caledonian Record
Patent Gives Allarity’s Cancer-Drug Pairing Exclusivity Into 2042 - Stock Titan
Allarity Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Allarity Therapeutics (ALLR) Advances 1.81% to $1.41, Pressing Against Key ResistanceAnalyst Upgrade Stocks - dars.gov.et
Allarity Therapeutics (ALLR) Edges Higher: Biotech Stock Tests Key $1.42 Resistance After +1.5% MoveVolume Oscillator - dars.gov.et
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - newsfilecorp.com
CNSY Stock Price and Chart — NASDAQ:CNSY - TradingView
Allarity Therapeutics (ALLR) Gains 2.48% as Stock Holds Above Key Support ZoneDividend ETF - dars.gov.et
Allarity Therapeutics Inc (ALLR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allarity Therapeutics (ALLR) Slips 1.65% as Stock Tests Key Support LevelsMoving Average Ribbon - vinanet.vn
Allarity Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALLR - TradingView
Allarity Therapeutics Inc (ALLR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Allarity Therapeutics Inc (ALLR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allarity Therapeutics Inc (ALLR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Allarity Therapeutics Inc (ALLR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
ALLR|Allarity Therapeutics Inc|Price:1.190| - TradingKey
TradingKey - TradingKey
Allarity Therapeutics Inc (ALLR) Income Statement - TradingKey
ALLR Q1 2026 Earnings: EPS Beat by 24.24% as Pre-Revenue Biotech Faces Market SkepticismEarnings Analysis - vinanet.vn
Allarity Therapeutics, Inc. (ALLR) stock price, news, quote and history - Yahoo Finance UK
Allarity Therapeutics, Inc. (ALLR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Allarity Therapeutics Inc (ALLR) News, Articles, Events & Latest Updates - Stocktwits
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance Australia
Allarity Therapeutics (ALLR) Rallies 4.9% as Buyers Hold $1.22 SupportCollar Trade - vinanet.vn
Update on One NASDAQ- Listed Pharmaceutical Stock– Allarity Therapeutics Inc - Kalkine
Allarity Therapeutics (ALLR) Edges Higher as Stock Tests Narrow Trading RangeTRIN Signal - dars.gov.et
Allarity Therapeutics Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Biotech Focuses on Pipeline ExecutionEstimate Accuracy - dars.gov.et
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Allarity Therapeutics - TMX Newsfile
Allarity Therapeutics (ALLR) Tests Support After 2.92% Decline – Key Levels Under ScrutinyLiquidity Sweep - dars.gov.et
Are medical stocks lagging Allarity Therapeutics, Inc. (ALLR) this year? - MSN
Allarity Therapeutics Obtains CLIA Certification For In-House DRP Testing And Advances Stenoparib Toward FDA Registration - marketscreener.com
Allarity Therapeutics obtains CLIA lab certification - Investing.com
Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration - Investing News Network
Allarity Therapeutics obtains CLIA lab certification By Investing.com - Investing.com Nigeria
Allarity’s Denmark lab gets CLIA status for U.S. cancer-trial testing - Stock Titan
ALLR Q1 2026 Earnings: Narrower-than-Expected Loss Fails to Offset Investor ConcernsAnalyst Earnings Estimate - DonanımHaber
Allarity Therapeutics Inc (ALLR) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):